How better tail spend visibility can strengthen pharma compliance
Discover how better tail spend visibility helps pharmaceutical organisations strengthen supplier compliance, reduce risk and improve resilience.
•
Articles

For pharmaceutical and life sciences organisations, effective tail spend management is about more than controlling procurement costs. Although tail spend typically represents around 10% of procurement expenditure, smaller suppliers can play critical roles in manufacturing, laboratory operations, equipment maintenance and quality assurance. Limited visibility into these relationships can expose organisations to regulatory compliance gaps, operational disruption and supplier risks that are disproportionate to their financial value.
A centralised supplier record brings together procurement, transaction and compliance data, enabling organisations to assess suppliers according to operational and regulatory risk rather than spend alone. AI-powered automation can support this process by identifying duplicate suppliers, classifying expenditure, monitoring certification expiry dates and streamlining onboarding. Combined with human oversight from procurement, quality and regulatory specialists, this approach strengthens supplier governance while maintaining proportionate controls.
Greater tail spend transparency also supports supply chain resilience, cost optimisation and more reliable Scope 3 emissions reporting. By connecting fragmented supplier information and establishing consistent, risk-based governance, pharmaceutical organisations can improve audit readiness, reduce administrative complexity and protect business continuity without creating unnecessary procurement barriers.
Read the full article on International Clinical Trials.




